Lallemand Health Solutions Awarded for Probiotic Research
10 Feb 2016 --- Lallemand Health Solutions is pleased to announce that innovative research presented by Jenna Ries won a Scientific Frontiers poster award at the recent Probiota 2016 event, in Amsterdam. This is the second year in a row that Lallemand probiotics research is rewarded at this industry event.
The winning poster described the development of a new, rapid method to detect the occurrence of rare pathogens in probiotics, using cutting edge technology. The proof of concept study presented is very promising and could constitute a first step towards quicker quality control assays in probiotic production. Such progress marks Lallemand Health Solutions commitment to R&D, not only to continuously document its strains benefits and modes of action, but also to improve its production processes and quality control, to better answer its customer’s needs.
Dr Pierre Burguière, Preclinical Research Program Manager at Lallemand Health Solutions in Montreal told NutritionInsight: “The reward reinforces the valued interest of the industry in developing novel methods for improving the probiotic production process, expediting product release and maintaining a high level of quality assurance to our clients.” Burguière adds, “The recognition of the benefit and utility of these novel methods will promote the standardization of rapid methods such as flow cytometry in industrial quality control applications, and ultimately increase the capacity of production for probiotic manufacturers, such as Lallemand Health Solutions.” Burguière believes the company will continue to a develop innovative technologies to meet the needs of the advancing industry into the future.
The work presented indicate that thanks to the application of sensitive detection technologies (mini VIDAS or Flow Cytometry) to probiotic samples, Salmonella detection could be realized in less than 22h, vs. several days using traditional microbiological methods.
Burguière adds: “Preclinical research of probiotics is vital to the success of Lallemand Health Solutions, not only to provide a scientific basis of behind the production of probiotic formulas for clinical studies, but also to better characterize strain-specific mechanisms of action to explore leading-edge applications of probiotics for human health.”
“Probiotic research is essential for the development, validation, and transfer of tools and techniques to enhance all stages of probiotic development, from bench to consumer, resulting in superior probiotic products,” he adds.
Burguière talks about future of Lallemand: “Future research on pathogen contaminant quality control will work towards evaluating the flow cytometry and mini VIDAS detection methods on a more representative model of contamination with dormant/ inactive pathogens. Further revision of the IMS-flow cytometry method will optimize pathogen specificity, throughput, and maximize efficiency (time to deliver results).”
by Elizabeth Kenward
